Charles River Laboratories Intl. Inc (NYSE:CRL) Insider Sells $162,819.64 in Stock

Share on StockTwits

Charles River Laboratories Intl. Inc (NYSE:CRL) insider David Ross Smith sold 1,249 shares of the company’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the transaction, the insider now directly owns 19,327 shares in the company, valued at $2,519,467.72. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Charles River Laboratories Intl. stock opened at $127.63 on Friday. Charles River Laboratories Intl. Inc has a 12-month low of $103.00 and a 12-month high of $149.07. The stock has a market capitalization of $6.38 billion, a P/E ratio of 21.62, a P/E/G ratio of 1.67 and a beta of 1.10. The firm’s 50-day moving average is $136.69 and its two-hundred day moving average is $136.67. The company has a debt-to-equity ratio of 1.47, a current ratio of 1.59 and a quick ratio of 1.38.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.55 by $0.08. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The company had revenue of $657.60 million for the quarter, compared to analysts’ expectations of $662.61 million. During the same period last year, the company earned $1.62 EPS. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. As a group, analysts forecast that Charles River Laboratories Intl. Inc will post 6.53 EPS for the current year.

Several hedge funds have recently made changes to their positions in CRL. Bank of New York Mellon Corp raised its holdings in Charles River Laboratories Intl. by 49.4% in the second quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock valued at $138,804,000 after buying an additional 323,625 shares during the period. AQR Capital Management LLC grew its position in shares of Charles River Laboratories Intl. by 18.0% during the first quarter. AQR Capital Management LLC now owns 2,082,761 shares of the medical research company’s stock worth $301,042,000 after buying an additional 317,001 shares in the last quarter. OZ Management LP acquired a new stake in shares of Charles River Laboratories Intl. during the first quarter worth approximately $44,308,000. Assenagon Asset Management S.A. grew its position in shares of Charles River Laboratories Intl. by 361.6% during the first quarter. Assenagon Asset Management S.A. now owns 335,619 shares of the medical research company’s stock worth $48,749,000 after buying an additional 262,907 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in shares of Charles River Laboratories Intl. by 18,244.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 241,596 shares of the medical research company’s stock worth $29,368,000 after buying an additional 240,279 shares in the last quarter. Institutional investors and hedge funds own 94.33% of the company’s stock.

A number of research firms have recently weighed in on CRL. Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Svb Leerink began coverage on shares of Charles River Laboratories Intl. in a research note on Monday, June 10th. They set an “outperform” rating and a $155.00 price target on the stock. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Leerink Swann began coverage on shares of Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating on the stock. Finally, Evercore ISI reissued an “outperform” rating and issued a $160.00 price objective on shares of Charles River Laboratories Intl. in a research note on Tuesday, April 30th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and an average target price of $147.29.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Do investors pay a separate front-end load every time they buy additional shares?

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Meridian Bioscience  Cut to Sell at ValuEngine
Meridian Bioscience Cut to Sell at ValuEngine
Trevena  Raised to “Buy” at Zacks Investment Research
Trevena Raised to “Buy” at Zacks Investment Research
2U  Now Covered by Analysts at William Blair
2U Now Covered by Analysts at William Blair
Aegis Reaffirms Buy Rating for Yield10 Bioscience
Aegis Reaffirms Buy Rating for Yield10 Bioscience
SunOpta, Inc.  Director Acquires $156,748.80 in Stock
SunOpta, Inc. Director Acquires $156,748.80 in Stock
First Majestic Silver Corp.  Senior Officer Sells C$179,375.00 in Stock
First Majestic Silver Corp. Senior Officer Sells C$179,375.00 in Stock


© 2006-2019 Ticker Report